PAION

PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that engages in developing and commercializing drug candidates for diseases or interventions with a substantial unmet medical need. The company’s lead compound is remimazolam, an intravenous, ultra-short-acting, and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside. The product can be used for general anesthesia in Europe and procedural sedation in the United States. It was founded in 2000 and is based in Aachen, Nordrhein-Westfalen, Germany.